Drug intelligence / Profile preview

BH2593

Development stage: Preclinical
Lead developer: Beijing Hanmei Pharmaceutical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BH2593 is an early-stage bispecific antibody candidate being developed by Beijing Hanmei Pharmaceutical for the treatment of various tumors. As of early 2024, the specific biological targets of the antibody remain undisclosed, and the program is in the discovery stage. The asset is part of Beijing Hanmei's oncology pipeline, which utilizes proprietary platforms to develop next-generation biologics designed to engage multiple therapeutic pathways or immune cell types simultaneously to improve efficacy in cancer treatment.

Beyond the preview

Go deeper on BH2593.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BH2593.

Explore the full profile